Corrigendum to "Decreased expression of KLF6 in ectopic endometrial stromal cells contributes to endometriosis progression by targeting CTNNB1" [Cellular Signalling 120 (2024) 111230].
The AGE-RAGE Pathway in Endometriosis: A Focused Mechanistic Review and Structured Evidence Map.
High Mobility Group Box 1 (HMGB1) and S100 proteins are major ligands of Receptor for Advanced Glycation End-products (RAGE) and have causal roles in endometriosis lesions. Yet the AGE-RAGE pathway …
Barriers affecting medication adherence to dienogest among patients with ovarian endometriosis: a qualitative study.
To explore barriers affecting medication adherence (e.g., missed doses, forgotten doses, or discontinuation) among patients with Ovarian Endometriosis (OE) using the Capability, Opportunity, Motivation - Behaviour (COM-B) behavioural change model …
Gut microbiota as a key regulator in endometriosis: mechanisms, therapeutic opportunities, and future perspectives.
Endometriosis (EMs), a common and frequently occurring gynecological disease, is a major cause of chronic pelvic pain and infertility in women. Its pathogenesis remains unclear to date, and it is …
Safety evaluation of percutaneous intrauterine hydrodissection in microwave ablation of uterine fibroids adjacent to the endometrium.
To assess the safety and efficacy of percutaneous intrauterine hydrodissection as a protective technique during microwave ablation (MWA) of uterine fibroids adjacent to the endometrium.
Relationship between serum CA125, prolactin and cortisol levels with disease stage and pain level in endometriosis patients.
Endometriosis affects approximately 10% of women of reproductive age and is characterized by the presence of endometrial tissue outside the uterine cavity. Diagnostic delays are common due to nonspecific symptoms …
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan - The Manila Times
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan The Manila Times